Views & Analysis | Perspectives on pharma industry issues

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Articles

Driving experiential digital engagement within pharma

We speak with Dominic Marchant and Matt Lowe about their new holographic presentation for the ABPI, and how technologies like this will push the digital space further in the future. In today’s competitive market, brands are constantly trying to find new ways to build awareness and...

Articles

Decision making and negotiation part one: technology licensi...

In the first of two articles on pharma decision-making, Jean-Louis Roux Dit Buisson discusses the concerns in technology licensing for pharmaceutical companies. Entrepreneurs, innovators and inventors are not necessarily educated in modern finance. One of their concerns when dealing...

Articles

Thoughts on digital from the ‘Social Media Jedi’

We interview the ‘Social Media Jedi’ Clive Roach, Social Media Strategist at Philips Healthcare, on successful digital campaigns and the online channels and tools that Clive finds most useful. Clive Roach, Social Media Strategist at Philips Healthcare, is heavily active in many social networks. Clive has his own blog, three Twitter...

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access